Perspective
Generic and therapeutic orphans
Abstract: This commentary discusses the need to develop methods to ensure the availability of non-profitable, off-patent medicines to children and other populations. The history and some of the shortcomings of… Read More »
Myths, questions, facts about generic drugs in the EU
Abstract: Many generic drugs are now being prescribed and the trend is increasing. For example, in Austria, the number of all generics prescriptions has more than doubled from 11% in… Read More »
Current understanding, knowledge, and perception of biosimilars in a changing landscape of regulatory requirements
Author byline as per print journal: Andriy Krendyukov, MD, PhD; Marta Bakowska, BA (Hon), MPH; Dirk Schiller, PhD; Sanjay Singhvi, BSc (Hon), MBBS, MBA Introduction: Healthcare providers often lack familiarity… Read More »
Comparative efficacy studies of biosimilars: data versus theoretical risks, beliefs, and comfort
Abstract: In principle, biosimilars could mitigate the problem of the rising cost of biological medicines. However, the current stringent and non-harmonized regulatory practices hinder competition and contribute to the… Read More »
Misinformation about interchangeable biosimilars undermines US health policy, physician confidence, and patient health
Author byline as per print journal: Michael S Reilly, Esq; Ralph D McKibbin, MD, FACP, FACG, AGAF Abstract: The US biosimilar program has been highly successful with 53 biosimilars approved… Read More »